Please login to the form below
OAB
This page shows the latest OAB news and features for those working in and with pharma, biotech and healthcare.
Daily Brief: setback for Akcea/Ionis, Urovant adds gene therapy, Metrion gains funding
Urovant Sciences has licensed a novel gene therapy for patients with overactive bladder (OAB) symptoms who have failed oral pharmacologic therapy. ... hMaxi-K has been evaluated in two phase I studies in OAB patients including a small phase 1b clinical
Latest news
-
Daily Brief: Limited NICE recommendation for Fasenra, Urovant takes aim at an IPO, Xtandi expands use
Urovant aims to investigate the drug’s use in overactive bladder (OAB), as well as another trial in OAB patients with benign prostatic hyperplasia, plus a third trial in patients with
-
Germany’s IQWiG denies Astellas’ incontinence drug
OAB). This review will be taken into consideration by the Federal Joint Committee (GBA), which will then recommend on whether the drug should be reimbursed on Germany's healthcare system. ... The decision is in contrast to the positive guidance from the
-
Astellas uses animated bladder in campaign
The campaign is for overactive bladder (OAB) drug Myrbetriq shows an untreated bladder character constantly interrupting a woman as she goes about her daily activities (see video above or on YouTube). ... The new campaign is aimed at women aged 45-69
-
Astellas gets first OK for prostate drug Vesomni
Urology is a core product franchise for Astellas, with its standalone Harnal (tamsulosin) product for BPH and overactive bladder (OAB) therapy Vesicare (solifenacin) bringing in sales of 67bn yen and 87bn ... The company has already added to its OAB
-
NICE recommends Astellas' Betmiga for overactive bladder
Final draft guidance recommends Vesicare successor
More from news
Approximately 1 fully matching, plus 13 partially matching documents found.
Latest Intelligence
-
Astellas: Ten years young
In Europe we have been launching a product almost every single year,” notes Ken, pointing to products such as the overactive bladder (OAB) drug Betmiga (mirabegron) - the first of a new ... class of OAB treatments to emerge in over 30 years, the
-
Interview: Kay Drake and Naoki Okamura, Astellas
For example, we are a GCL in urology; we have Vesicare, which has 40 per cent market share in the overactive bladder (OAB) market. ... From an OAB perspective, we support the Bladder and Bowel Foundation here in the UK, which provides a patient advice
More from intelligence
Approximately 0 fully matching, plus 2 partially matching documents found.
Latest appointments
-
Astellas strengthens US and Canadian leadership team
As Sabus leaves from the US, Astellas has promoted Lynn Fenicchia Gerber (pictured left) to US vice president, primary care, where she will lead sales efforts for the OAB, anti-fungal,
More from appointments
Approximately 0 fully matching, plus 1 partially matching documents found.
Latest from PMHub
-
emotive project Decisions in Time wins gold for the Digital solution for congress/symposium at the 2014 PM Digital Media Awards
Other emotive projects OAB Health Economics won silver in the Craft Award – Mobile and Diabetes Voyager won bronze in the Innovation Award – Pushing Boundaries.
-
Award-winning emotive project, Decisions in Time, nominated as a finalist in yet more pharmaceutical awards
Along with emotive projects like Diabetes Voyager and OAB Health Economics and Neil Kumar being nominated for Account Manager of the Year, emotive is a finalist for a total of six
-
emotive client Adam Boucher of Novo Nordisk announced as a finalist for Digital Pioneer at the 2014 PM Digital Awards
OAB Health Economics app has been nominated in the Craft Award – Mobile category. -
-
Neil Kumar announced as a finalist for Account Manager of the Year at the PM Society Digital Media Awards 2014
OAB Health Economics app.
-
emotive is thrilled to be a sponsor of the PM Society’s Digital Media Awards 2014
Craft Award – Mobile for OAB Health Economics.
More from PMHub
Approximately 0 fully matching, plus 8 partially matching documents found.
Featured jobs
-
Business Director
-
Competitive Salary Offered
- Business Development Director – Health Education
-
excellent commission
- Account Executive/ Senior Account Executive
-
competitive Salary Offfered
-
Associate Medical Director
-
Excellent PTO, bonus and 401k package
-
Account Manager
-
Negotiable
- Account Manager- Healthcare Advertising
-
Negotiable
- Scientific Director – Medical Communications - New York or Remot...
-
$100000 - $150000
- Account Manager / Senior Account Manager
-
35, 000-40, 000
-
Account Manager / Account Director
-
Competative
-
Associate Director
-
£75, 000-90, 000
-
Account Director
-
Competitive Salary Offered
-
Senior Account Manager
-
Competitive Salary Offered
- Account Manager- Healthcare Advertising
-
Negotiable
Subscribe to our email news alerts
- Industry frustrated by late warning on 'no deal' Brexit disruption
- UK’s genomics leadership attracts IQVIA investment, regardless of Brexit
- Lucid Group celebrate another magical year at their Winter Meeting
- Biogen picks up another drug from wide-ranging Ionis alliance
- As France protests, Sanofi takes axe to 670 jobs
- Leicester NHS Trust’s staff intranet is integral to HCPs’ working day
PMHub
Porterhouse Medical Group
The Porterhouse Medical Group provides market research, insights, and scientific and medical communication services to the pharmaceutical industry across the...
Latest intelligence
- Marketing to healthcare professionals – what’s the key ingredient missing from most campaigns?
- What do you think is the difference between a campaign developed to win a share-of-mind with consumers and a campaign designed to gain the attention of healthcare professionals?...
- What everyone forgets about good organisational change in pharma
- Natasha Cowan speaks to Daphne Chung, Head of Organisational Transformation, to learn how she ensures smooth organisational change that takes all stakeholders into account....
- Live from Singapore: Oncology in APAC - Evaluating the opportunity for novel therapies
- Live webinar: Tuesday 11th December 2018,16:00 SGT / 17:00 JST...
Quick links
Infographics
